Rare occurrence of inflammatory bowel disease in a cohort of Han Chinese ankylosing spondylitis patients-a single institute study

被引:11
作者
Wang, Chrong-Reen [1 ]
Weng, Chia-Tse [1 ]
Lee, Chung-Ta [2 ]
Huang, Kuo-Yuan [3 ]
Hsu, Sheng-Min [4 ]
Liu, Ming-Fei [1 ]
机构
[1] Natl Cheng Kung Univ Hosp, Dept Internal Med, Tainan, Taiwan
[2] Natl Cheng Kung Univ Hosp, Pathol, Tainan, Taiwan
[3] Natl Cheng Kung Univ Hosp, Orthopaed, Tainan, Taiwan
[4] Natl Cheng Kung Univ Hosp, Opthalmol, Tainan, Taiwan
来源
SCIENTIFIC REPORTS | 2017年 / 7卷
关键词
PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; CROHNS-DISEASE; ADALIMUMAB; EFFICACY; SAFETY; ETANERCEPT; INFLIXIMAB; MULTICENTER; THERAPY;
D O I
10.1038/s41598-017-13573-z
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Despite a high prevalence of ankylosing spondylitis (AS) in Han Chinese, the clinical experience remains very limited in the extra-articular presentation of inflammatory bowel disease (IBD). A monocentric retrospective study was performed for the AS-associated IBD manifestation. This study analyzed AS patients fulfilling the 1984 revised New York diagnostic criteria, excluding those who had the onset of IBD before or concurrently with the diagnosis of AS, for their demographic, clinical, laboratory, radiological, pathological and medication data, particularly in the usage of anti-TNF monoclonal antibody. Among 988 AS patients with 19.8% female, 4 (0.4%) had the overt IBD presentation, one female and 3 male aged 28 to 47 years (38.8 +/- 4.6), all ulcerative colitis with the characteristic histopathological findings. At the onset of colitis, all had a long-term disease duration of 10 to 25 years (17.5 +/- 6.5) and high BASDAI 7.5 to 8.8 (8.2 +/- 0.5) with the hip joint involvement. There were recurrent flares of colitis despite the treatment with corticosteroids and messalazopyrin/salazopyrin, and no relapses of IBD were observed for 6.0 +/- 1.1 years after the adalimumab (ADA) therapy. In this retrospective cohort, we demonstrate the rarity of AS-associated IBD manifestation in Han Chinese with a beneficent effect from the ADA therapy.
引用
收藏
页数:6
相关论文
共 42 条
[1]   Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept:: Clinical and magnetic resonance imaging data [J].
Baraliakos, X ;
Brandt, J ;
Listing, J ;
Haibel, H ;
Sörensen, H ;
Rudwaleit, M ;
Sieper, J ;
Braun, J .
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2005, 53 (06) :856-863
[2]   Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis [J].
Brandt, J ;
Khariouzov, A ;
Listing, J ;
Haibel, H ;
Sörensen, H ;
Grassnickel, L ;
Rudwaleit, M ;
Sieper, J ;
Braun, J .
ARTHRITIS AND RHEUMATISM, 2003, 48 (06) :1667-1675
[3]   Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis [J].
Braun, J ;
Brandt, J ;
Listing, J ;
Zink, A ;
Alten, R ;
Burmester, G ;
Gromnica-Ihle, E ;
Kellner, H ;
Schneider, M ;
Sörensen, H ;
Zeidler, H ;
Sieper, J .
ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 (02) :229-234
[4]   Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis -: An open, observational, extension study of a three-month, randomized, placebo-controlled trial [J].
Braun, J ;
Brandt, J ;
Listing, J ;
Zink, A ;
Alten, R ;
Burmester, G ;
Golder, W ;
Gromnica-Ihle, E ;
Kellner, H ;
Schneider, M ;
Sörensen, H ;
Zeidler, H ;
Reddig, J ;
Sieper, J .
ARTHRITIS AND RHEUMATISM, 2003, 48 (08) :2224-2233
[5]   Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor α agents [J].
Braun, J. ;
Baraliakos, X. ;
Listing, J. ;
Davis, J. ;
Van der Heijde, D. ;
Haibel, H. ;
Rudwaleit, M. ;
Sieper, J. .
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2007, 57 (04) :639-647
[6]   Treatment of active ankylosing spondylitis with infliximab:: a randomised controlled multicentre trial [J].
Braun, J ;
Brandt, J ;
Listing, J ;
Zink, A ;
Alten, R ;
Golder, W ;
Gromica-Ihle, E ;
Kellner, H ;
Krause, A ;
Schneider, M ;
Sörensen, H ;
Zeidler, H ;
Thriene, W ;
Sieper, J .
LANCET, 2002, 359 (9313) :1187-1193
[7]   Persistent clinical response to the anti-TNF-α antibody infliximab in patients with ankylosing spondylitis over 3 years [J].
Braun, J ;
Baraliakos, X ;
Brandt, J ;
Listing, J ;
Zink, A ;
Alten, R ;
Burmester, G ;
Gromnica-Ihle, E ;
Kellner, H ;
Schneider, M ;
Sörensen, H ;
Zeidler, H ;
Sieper, J .
RHEUMATOLOGY, 2005, 44 (05) :670-676
[8]   Review article: the histological assessment of disease activity in ulcerative colitis [J].
Bressenot, A. Marchal ;
Riddell, R. H. ;
Boulagnon-Rombi, C. ;
Reinisch, W. ;
Danese, S. ;
Schreiber, S. ;
Peyrin-Biroulet, L. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2015, 42 (08) :957-967
[9]   Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis [J].
Calin, A ;
Dijkmans, BAC ;
Emery, P ;
Hakala, M ;
Kalden, J ;
Leirisalo-Repo, M ;
Mola, EM ;
Salvarani, C ;
Sanmartí, R ;
Sany, J ;
Sibilia, J ;
Sieper, J ;
van der Linden, S ;
Veys, E ;
Appel, AM ;
Fatenejad, S .
ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 (12) :1594-1600
[10]   Safety and Efficacy of Adalimumab for Patients With Moderate to Severe Crohn's Disease: The Taiwan Society of Inflammatory Bowel Disease (TSIBD) Study [J].
Chang, Chen-Wang ;
Wei, Shu-Chen ;
Chou, Jen-Wei ;
Hsu, Tzu-Chi ;
Chuang, Chiao-Hsiung ;
Lin, Ching-Pin ;
Hsu, Wen-Hung ;
Yen, Hsu-Heng ;
Lin, Jen-Kou ;
Fang, Yi-Jen ;
Wang, Horng-Yuan ;
Lin, Hung-Hsin ;
Wu, Deng Cheng ;
Ni, Yen Hsuan ;
Wang, Cheng-Yi ;
Wong, Jau-Min .
INTESTINAL RESEARCH, 2014, 12 (04) :287-292